Ahmedabad, Gujarat, India, January 2025 – Intas Pharmaceuticals is proud to announce the appointment of Dr. Pramod Kharwade as Vice President – Formulation & Development. Dr. Kharwade brings over 23 years of expertise in formulation research and development, with an impressive record of delivering and submitting more than 100 generic products. His strategic leadership and commitment to innovation will play a pivotal role in driving advancements in Intas’ formulation and development initiatives.
Dr. Kharwade began his tenure at Intas Pharmaceuticals in December 2024, leveraging his extensive expertise to spearhead formulation strategies and product development. Before joining Intas, he served at Biocon for nearly five years as Associate Vice President, where he led innovative formulation initiatives and streamlined project management processes.
Prior to Biocon, Dr. Kharwade held various senior roles at Glenmark Pharmaceuticals, including General Manager and Senior Principal Scientist, contributing significantly to formulation development and product pipelines. His career also includes over seven years at Dr. Reddy’s Laboratories, where he progressed from Deputy Manager to Associate Director, focusing on formulation development and project management.
Earlier in his career, Dr. Kharwade worked as a Research Scientist at Ranbaxy, laying the foundation for his expertise in pharmaceutical innovation. His academic background includes an M.Pharm from Birla Institute of Technology and Science, Pilani, equipping him with a robust foundation in pharmaceutical sciences.
About Intas Pharmaceuticals
Intas Pharmaceuticals is a leading global pharmaceutical formulation development, manufacturing, and marketing organization. With a strong presence in over 85 countries and more than 70% of revenue from international markets, Intas has established itself as a key player in the pharmaceutical industry. The company operates 17 advanced R&D and distribution facilities, accredited by global regulators such as USFDA, EMA, and TGA, among others.
Intas continues to drive innovation with its investments in R&D, focusing on biosimilars, NDDS products, and high-value therapies. The company’s vision is powered by its commitment to innovation, customer delight, collaboration, and societal care, ensuring its leadership in therapeutic segments like CNS, oncology, urology, and more.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
